Alto Neuroscience, Inc. (ANRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alto Neuroscience, Inc. on July 3, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Mountain View, California. The report details a corporate action regarding the repricing of underwater stock options approved by the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to equity compensation:
- Stock Price: $2.35 per share (Closing price on July 3, 2025).
- Total Eligible Options Repriced: 4,225,763 shares.
- Original Exercise Price Range: $2.44 to $16.00 per share.
- New Exercise Price: $2.35 per share (subject to retention requirements).
Material Changes
The primary material change is the repricing of designated underwater stock options effective July 3, 2025. The Board reduced the exercise price of eligible options to the current market price of $2.35. This action applies to options held by current employees and consultants under the 2019 and 2024 Equity Incentive Plans. Notably, options held by non-employee Board members were excluded. The number of shares, vesting schedules, and expiration dates remain unchanged.
Guidance, Outlook, and Management Commentary
Management Rationale: The Board approved the repricing to retain and motivate key personnel without incurring significant stock dilution from new grants or additional cash compensation. The decision followed a review by an independent compensation consultant.
Retention Requirements: To exercise options at the reduced price of $2.35, participants must remain in service through a "Retention Period" ending on the earliest of: (i) 12 months from the Effective Date, (ii) a Change in Control where options are not assumed/substituted, or (iii) a Qualifying Termination (death, disability, or termination without Cause).
Penalty for Early Exercise: If an eligible participant exercises options before the Retention Period ends, they must pay the original, higher exercise price.
Key Personnel Affected:
- Dr. Amit Etkin (CEO): 719,910 shares (Original prices: $4.20 - $14.88).
- Nicholas Smith (CFO/CBO): 506,124 shares (Original prices: $4.20 - $14.88).
- Michael Hanley (COO): 321,000 shares (Original prices: $4.20 - $14.88).
Investor Verification Checklist
- Verify the impact of the 4,225,763 repriced options on potential future dilution if exercised after the retention period.
- Confirm the current market price of ANRO stock relative to the new $2.35 strike price to assess immediate intrinsic value.
- Review the specific definitions of "Qualifying Termination" and "Cause" in the 2019 and 2024 Equity Incentive Plans to understand vesting acceleration risks.
- Monitor future filings for any changes in executive turnover during the 12-month retention period.